Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
ACRX [NASD]
AcelRx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.32 Insider Own0.20% Shs Outstand43.38M Perf Week4.36%
Market Cap301.06M Forward P/E- EPS next Y-1.14 Insider Trans11.57% Shs Float42.66M Perf Month30.21%
Income-13.40M PEG- EPS next Q-0.22 Inst Own85.80% Short Float20.81% Perf Quarter0.73%
Sales28.30M P/S10.64 EPS this Y60.90% Inst Trans-0.30% Short Ratio12.61 Perf Half Y-34.34%
Book/sh1.28 P/B5.42 EPS next Y-6.50% ROA-13.70% Target Price11.33 Perf Year4.36%
Cash/sh2.13 P/C3.26 EPS next 5Y- ROE-21.70% 52W Range5.22 - 13.64 Perf YTD-38.64%
Dividend- P/FCF- EPS past 5Y11.10% ROI-7.60% 52W High-49.12% Beta1.83
Dividend %- Quick Ratio10.70 Sales past 5Y- Gross Margin- 52W Low32.95% ATR0.44
Employees44 Current Ratio10.70 Sales Q/Q-82.60% Oper. Margin-32.20% RSI (14)54.72 Volatility4.65% 6.86%
OptionableYes Debt/Eq0.44 EPS Q/Q48.90% Profit Margin-47.30% Rel Volume0.59 Prev Close6.75
ShortableYes LT Debt/Eq0.40 EarningsNov 03 AMC Payout- Avg Volume703.66K Price6.94
Recom2.10 SMA207.99% SMA502.62% SMA200-26.28% Volume425,027 Change2.81%
26-Sep-14Downgrade ROTH Capital Buy → Neutral
28-Jul-14Reiterated RBC Capital Mkts Outperform $15 → $12
28-Jul-14Reiterated Mizuho Buy $20 → $15
28-Jul-14Downgrade Canaccord Genuity Buy → Hold
17-Apr-14Initiated Canaccord Genuity Buy $16
07-Jan-14Initiated RBC Capital Mkts Outperform $15
19-Dec-13Reiterated Mizuho Buy $18 → $20
17-Dec-13Reiterated MLV & Co Buy $15 → $16.50
17-Jul-13Reiterated Mizuho Neutral $13 → $18
04-Feb-13Initiated MLV & Co Buy $13
30-Jan-13Initiated Mizuho Buy $13
10-Oct-12Resumed Canaccord Genuity Buy $8
26-May-11Initiated Canaccord Genuity Buy $6
29-Oct-14 01:04PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in AcelRx Pharmaceuticals, Inc. to Contact Brower Piven Before the December 1, 2014 Lead Plaintiff Deadline in Class Action Lawsuit - GlobeNewswire
07:53AM  Can The Uptrend Continue for AcelRx Pharmaceuticals (ACRX)? Zacks
27-Oct-14 04:27PM  UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against AcelRx Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 1, 2014 -- ACRX Marketwired
07:00AM  AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentations At The American College Of Surgeons Meeting PR Newswire
22-Oct-14 02:40PM  EQUITY ALERT: Rosen Law Firm P.A. Reminds AcelRx Pharmaceuticals, Inc. Investors of Important Class Action Deadline - ACRX GlobeNewswire
07:00AM  AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results PR Newswire
20-Oct-14 12:42PM  UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against AcelRx Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 1, 2014 -- ACRX GlobeNewswire
16-Oct-14 07:00AM  AcelRx Pharmaceuticals Provides Update on its Patent Portfolio for Zalviso and its Proprietary Platform Technologies PR Newswire +6.83%
15-Oct-14 08:26PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit Business Wire +6.17%
10-Oct-14 07:30PM  Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against AcelRx Pharmaceuticals, Inc. -- ACRX GlobeNewswire
06:37PM  INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $50,000 Investing in AcelRx Pharmaceuticals, Inc. (ACRX) to Contact the Firm Marketwired
07:00AM  AcelRx Pharmaceuticals Announces Multiple Sublingual Sufentanil Data Presentations At The American Society Of Anesthesiologists Meeting PR Newswire
08-Oct-14 01:52PM  Robbins Arroyo LLP: AcelRx Pharmaceuticals, Inc. (ACRX) Misled Shareholders According to a Recently Filed Class Action GlobeNewswire
07-Oct-14 08:35PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in AcelRx Pharmaceuticals, Inc. to Contact Brower Piven Before the December 1, 2014 Lead Plaintiff Deadline in Class Action Lawsuit - GlobeNewswire
08:00PM  Harwood Feffer LLP Announces Investigation of AcelRx Pharmaceuticals, Inc. PR Newswire
06:31PM  Lifshitz & Miller Law Firm Announces Investigation of AcelRx Pharmaceuticals, Inc., Ambit Biosciences, Athlon Energy Inc., LipoScience, Inc., Simplicity Bancorp, Inc., and TIBCO Software Inc. PR Newswire
11:10AM  AcelRx Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors Business Wire
06-Oct-14 05:54PM  Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. Marketwired
02:21PM  EQUITY ALERT: The Rosen Law Firm P.A. Announced Filing of Securities Class Action Against AcelRx Pharmaceuticals, Inc. - ACRX GlobeNewswire
02:08PM  UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Investors of Class Action Against AcelRx Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 1, 2014 -- ACRX GlobeNewswire
07:00AM  Sufentanil sublingual tablet system study results to be presented at the International Association for the Study of Pain Meeting PR Newswire
03-Oct-14 07:15PM  INVESTOR ALERT: Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. Announced by Law Offices of Howard G. Smith Business Wire
04:00PM  INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In AcelRx Pharmaceuticals, Inc. (ACRX) To Contact The Firm PR Newswire
02-Oct-14 10:32AM  INVESTOR ALERT: Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. Filed By Glancy Binkow & Goldberg LLP Business Wire
29-Sep-14 02:45PM  SHAREHOLDER ALERT: Investigation on Behalf of AcelRx Pharmaceuticals, Inc. Investors Announced by Law Offices of Howard G. Smith Business Wire +9.06%
10:40AM  INVESTOR ALERT: Investigation on Behalf of AcelRx Pharmaceuticals, Inc. Shareholders Announced by Glancy Binkow & Goldberg LLP Business Wire
26-Sep-14 04:35PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online -19.49%
03:23PM  Why AcelRx Pharmaceuticals (ACRX) Stock Hit a One-Year Low Today at TheStreet
12:42PM  AcelRx downgraded by ROTH Capital Briefing.com
11:22AM  Midday movers: Apple, RadioShack, Shutterfly & more at CNBC
09:34AM  [$$] AcelRx Shares Slide on FDA Delay at The Wall Street Journal
07:00AM  AcelRx Pharmaceuticals Provides Regulatory Update on Zalviso PR Newswire
10-Sep-14 07:00AM  AcelRx Announces Publication of Manuscript Analyzing Cost of Intravenous Patient-Controlled Analgesia with Opioids PR Newswire
04-Sep-14 07:00AM  AcelRx Announces Publication of Sufentanil Sublingual Tablet System vs. Intravenous Patient-Controlled Analgesia with Morphine for Postoperative Pain Study Results PR Newswire
27-Aug-14 07:00AM  AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events PR Newswire
26-Aug-14 02:22PM  The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks at TheStreet
19-Aug-14 01:04PM  ACELRX PHARMACEUTICALS INC Financials EDGAR Online Financials
11-Aug-14 05:01PM  ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
04:00PM  AcelRx Pharmaceuticals Reports Second Quarter 2014 Financial Results PR Newswire
07:07AM  Q2 2014 AcelRx Pharmaceuticals, Inc. Earnings Release - After Market Close CCBN
08-Aug-14 07:00AM  AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events PR Newswire
07-Aug-14 07:00AM  AcelRx Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Monday, August 11th, 2014. PR Newswire
01-Aug-14 08:16AM  AcelRx Pharmaceuticals (ACRX) Soars: Stock Adds 6.8% in Session Zacks
07:00AM  4 Biotech Stocks Under $10 to Trade for Breakouts at TheStreet
29-Jul-14 06:03PM  Nasdaq stocks posting largest percentage decreases AP
10:20AM  Today's Dead Cat Bounce Stock: AcelRx Pharmaceuticals (ACRX) at TheStreet
08:40AM  Top Analyst Upgrades and Downgrades: AcelRx, Alcoa, Costco, Lululemon, Walmart, Trulia and More at 24/7 Wall St.
28-Jul-14 04:32PM  U.S. Stocks Little Changed on Mergers, Data Before Fed Bloomberg -41.00%
04:15PM  Dow, S&P 500 inch up, while Nasdaq, Russell 2000 slip: stock market live blog recap at MarketWatch
04:05PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
02:35PM  AcelRx Pharma Plunges After FDA Rejects Device at Investor's Business Daily
10:07AM  Why AcelRx Pharmaceuticals (ACRX) Stock Is Plummeting Today at TheStreet
09:44AM  FDA Rejects AcelRx Painkiller Dispensing Device (Update) at TheStreet
09:35AM  [video] Mon., July 28: Family Dollar Among Stocks to Watch at MarketWatch
09:15AM  AcelRX Selling Off Sharply On FDA Reexamination Benzinga
08:48AM  AcelRx stock plunges after FDA rejects pain drug device Reuters
27-Jul-14 01:25PM  FDA issues Complete Response Letter for AcelRx NDA for Zalviso at theflyonthewall.com
25-Jul-14 09:59PM  AcelRx Pharmaceuticals Receives Complete Response Letter from FDA for New Drug Application for Zalviso PR Newswire +5.97%
02:52PM  Why AcelRx Pharmaceuticals Inc Stock Boomed at Motley Fool
24-Jul-14 11:49PM  AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso PR Newswire
23-Jul-14 09:01AM  Edelman's Perceptive Advisors Buying Amicus Therapeutics Ahead Of Phase III Data Release at Seeking Alpha +6.73%
07:52AM  Shorting AcelRx Into PDUFA: A Risky Proposition at Seeking Alpha
21-Jul-14 01:19PM  Nasdaq stocks posting largest percentage increases AP
07:06AM  AcelRx Pharmaceuticals (ACRX) Jumps: Stock Adds 11.7% in Session Zacks
07-Jul-14 10:13AM  AcelRx's Upcoming PDUFA And Trade Recommendations at Seeking Alpha
03:00AM  AcelRx and Grunenthal Announce Submission of European Marketing Authorization Application for ZALVISO PR Newswire
03-Jul-14 09:04AM  5 Stocks Spiking on Unusual Volume at TheStreet
02-Jul-14 08:30AM  AcelRx Should Trend Higher As FDA Approval Is Likely At End Of This Month at Seeking Alpha
19-Jun-14 07:00AM  AcelRx Pharmaceuticals to Present at the JMP Securities Healthcare Conference PR Newswire -5.10%
17-Jun-14 09:47AM  AcelRx Pharmaceuticals (ACRX) Jumps: Stock Rises 9.0% Zacks
16-Jun-14 04:35PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Of EDGAR Online +8.95%
03-Jun-14 07:00AM  Results of Cost Analysis Study Presented at ISPOR Meeting Identify Intravenous Patient-Controlled Analgesia (IV PCA) Costs of $200 to $240 for Two Days of Post-Surgical Pain Management PR Newswire
02-Jun-14 04:31PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
04:13PM  AcelRx Pharmaceuticals Announces The Departure Of David Chung PR Newswire
29-May-14 08:00AM  AcelRx Pharmaceuticals to Present at the Jefferies Global Healthcare Conference PR Newswire
06:09AM  AcelRx management to meet with Piper Jaffray at theflyonthewall.com
19-May-14 05:17PM  AcelRx files to sell 3.07M shares of common stock for holders at theflyonthewall.com
05:16PM  AcelRx files $150M mixed securities shelf at theflyonthewall.com
12:10PM  AcelRx management to meet with Jefferies at theflyonthewall.com
11:59AM  AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference PR Newswire
08-May-14 09:51PM  AcelRx Pharmaceuticals' (ACRX) CEO Richard King on Q1 2014 Results - Earnings Call Transcript at Seeking Alpha
05:13PM  ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
04:36PM  AcelRx believes it has funds for operations at least through 2015 at theflyonthewall.com
04:34PM  AcelRx reports Q1 EPS (22c), consensus (23c) at theflyonthewall.com
04:05PM  AcelRx Pharmaceuticals Reports First Quarter 2014 Financial Results PR Newswire
07:07AM  Q1 2014 AcelRx Pharmaceuticals, Inc. Earnings Release - After Market Close CCBN
07-May-14 04:17PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan EDGAR Online
02-May-14 07:30AM  AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Thursday, May 8, 2014 PR Newswire
01-May-14 07:30AM  AcelRx Pharmaceuticals Announces Zalviso and ARX-04 Data Presentations at the American Pain Society 33rd Annual Scientific Meeting PR Newswire
04-Apr-14 07:30AM  AcelRx Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference PR Newswire
01-Apr-14 05:05PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
25-Mar-14 05:03PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex EDGAR Online
07:30AM  AcelRx Pharmaceuticals Appoints Timothy E. Morris as Chief Financial Officer PR Newswire
17-Mar-14 05:19PM  ACELRX PHARMACEUTICALS INC Files SEC form 10-K, Annual Report EDGAR Online
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain (BTP). Its principal product candidate is Zalviso, an investigational pre-programmed, non-invasive, handheld system that has completed Phase III clinical trials for the treatment of moderate-to-severe acute pain in adult patients in the hospital setting. The company is also developing ARX-04, a Sufentanil Single-Dose NanoTab, which has completed Phase II clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in settings of acute pain, such as on the battlefield, in the emergency room, or in ambulatory care facilities. In addition, its product candidate pipeline consists of ARX-02, a Sufentanil NanoTab pain management system, which has completed Phase II clinical trials for the treatment of cancer patients who suffer from breakthrough pain (BTP); and ARX-03, a Sufentanil/Triazolam NanoTab, a Phase II clinical trials completed product designed to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WAN MARK ADirectorMar 10Sale12.36835,32710,324,642126,153Mar 11 02:34 PM
WAN MARK ADirectorMar 07Sale12.30164,6732,025,400137,403Mar 11 02:34 PM